Literature DB >> 14993020

Correlation between prognostic factors and increasing age in melanoma.

Celia Chao1, Robert C G Martin, Merrick I Ross, Douglas S Reintgen, Michael J Edwards, R Dirk Noyes, Lee J Hagendoorn, Arnold J Stromberg, Kelly M McMasters.   

Abstract

BACKGROUND: Age of patients with melanoma varies directly with mortality and inversely with the presence of sentinel lymph node (SLN) metastasis. To gain further insight into this apparent paradox, we analyzed the relationship between age and other major prognostic factors.
METHODS: The Sunbelt Melanoma Trial is a prospective, randomized study with 79 institutions involving SLN biopsy for melanoma. Eligible patients were 18 to 70 years old with melanoma of > or = 1.0-mm Breslow thickness and clinically N0 regional lymph nodes. SLNs were evaluated by serial histological sections and immunohistochemistry for S-100 protein.
RESULTS: A total of 3076 patients were enrolled in the study, with a median follow-up of 19 months. Five age groups were examined: 18 to 30, 31 to 40, 41 to 50, 51 to 60, and 61 to 70 years. Trends between age and several key prognostic factors was identified: as age group increased, so did Breslow thickness (analysis of variance; P <.001), the incidence of ulceration and regression, and the proportion of male patients (each variable: chi2, P <.001). The incidence of SLN metastasis, however, declined with increasing age (chi2; P <.001).
CONCLUSIONS: As age increases, so does Breslow thickness, the incidence of ulceration and regression, and the proportion of male patients-all poor prognostic factors. However, the frequency of SLN metastasis declines with increasing age. It is not known whether this represents a decreased sensitivity (higher false-negative rate) of the SLN procedure in older patients or a different biological behavior (hematogenous spread) of melanomas in older patients.

Entities:  

Mesh:

Year:  2004        PMID: 14993020     DOI: 10.1245/aso.2004.04.015

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  46 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

3.  Sentinel lymph node biopsy in malignant melanoma.

Authors:  J Meirion Thomas
Journal:  BMJ       Date:  2008-04-26

4.  Management of regional lymph node basins in melanoma.

Authors:  Timothy P Love; Keith A Delman
Journal:  Ochsner J       Date:  2010

Review 5.  Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.

Authors:  Athanassios Kyrgidis; Thrasivoulos Tzellos; Simone Mocellin; Zoe Apalla; Aimilios Lallas; Pierluigi Pilati; Alexander Stratigos
Journal:  Cochrane Database Syst Rev       Date:  2015-05-16

6.  Post-surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003-2015).

Authors:  Travis Laver; Brittany R Feldhaeusser; Cecilia S Robat; Jennifer L Baez; Kim L Cronin; Paolo Buracco; Maurizio Annoni; Rebecca C Regan; Sarah K McMillan; Kaitlin M Curran; Laura E Selmic; Kai-Biu Shiu; Kyle Clark; Erin Fagan; Douglas H Thamm
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

7.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Authors:  Samudra K Dissanayake; Purevdorj B Olkhanud; Michael P O'Connell; Arnell Carter; Amanda D French; Tura C Camilli; Chineye D Emeche; Kyle J Hewitt; Devin T Rosenthal; Poloko D Leotlela; Michael S Wade; Sherry W Yang; Larry Brant; Brian J Nickoloff; Jane L Messina; Arya Biragyn; Keith S Hoek; Dennis D Taub; Dan L Longo; Vernon K Sondak; Stephen M Hewitt; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Increasing Incidence of Melanoma in the Elderly: An Epidemiological Study in Olmsted County, Minnesota.

Authors:  Jeannette M Olazagasti Lourido; Janice E Ma; Christine M Lohse; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2016-09-28       Impact factor: 7.616

Review 9.  Melanoma in pediatric, adolescent, and young adult patients.

Authors:  John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

10.  Age-related lymphatic dysfunction in melanoma patients.

Authors:  W Charles Conway; Mark B Faries; Michael B Nicholl; Alicia M Terando; Edwin C Glass; MyungShin Sim; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-03-11       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.